A preclinical study suggested that melanoma-associated fibroblasts (MAFs), significantly impair the generation of melanoma-specific T-cell responses and compromise the efficacy of anti-PD-1 checkpoint inhibition (63). Here, PDCD1 is linked to melanoma.